News

27Jan '20

Atnahs Acquires Rights to Established Hypertension Medicines

Basildon / Cambridge (UK), 27 January 2020 – Atnahs, a Triton Fund V portfolio company, has signed an agreement to acquire the global (ex-China, India, Japan and US) commercial rights to a portfolio of Cardiovascular medicines used primarily to treat hypertension – namely, Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose…

Read more

08Aug '19

Triton Completes Acquisition of a Majority Stake in Atnahs

Frankfurt (Germany), Basildon (United Kingdom), August 8, 2019 – Funds advised by Triton have successfully completed the acquisition of a majority stake of Atnahs, a specialty pharmaceutical business, focussed on the acquisition, development and marketing of mature branded medicines. Terms and conditions of the transaction are not disclosed. About Atnahs Atnahs is a specialty pharmaceutical…

Read more

14Dec '18

Atnahs Acquires Famvir®

Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of Famvir® from Novartis. Famvir® (famciclovir) is an antiviral used primarily as a treatment for herpes. Amit Patel, Atnahs’ Managing Director, comments, “The acquisition of Famvir® continues our strategy of acquiring and marketing trusted brands, and it reinforces our presence in key…

Read more

01Dec '18

Atnahs Opens New Branch in the United Arab Emirates (UAE)

Dubai, UAE. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the opening of a new branch in Dubai, UAE. This will house Sales staff focused upon developing Atnahs’ business throughout the Middle East and North Africa. Dipen Patel, the General Manager of the new branch, comments, “This is the next step in Atnahs’ strategy…

Read more

28Feb '18

Atnahs Acquires Remaining Stake in Pharmanovia A/S in Denmark

Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of the remaining share capital of Pharmanovia A/S (“Pharmanovia”). Pharmanovia focuses upon developing and marketing niche pharmaceutical products and medical devices in the Nordics and beyond. Notably, it is in the process a launching Dropizol® (opium oral drops for the treatment of severe diarrhoea…

Read more

01Nov '17

Atnahs Launches Traxidot® (Tranexamic Acid) in the Netherlands

Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the launch of Traxidot® (Tranexamic Acid) 100mg/ml ampoules for injection (5 ampoules of 5ml) in the Netherlands. Tranexamic Acid is used for the reduction of heavy menstrual bleeding. Amit Patel, Atnahs’ Managing Director, comments, “Tranexamic Acid is the latest addition to Atnahs’ portfolio of…

Read more